Sesen Bio Inc
F:PCBK
Sesen Bio Inc
Other Items
Sesen Bio Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sesen Bio Inc
F:PCBK
|
Other Items
-$54m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.9B
|
CAGR 3-Years
-108%
|
CAGR 5-Years
31%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
26%
|
CAGR 10-Years
13%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Other Items
$135.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
43%
|
CAGR 10-Years
39%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$1.1B
|
CAGR 3-Years
-111%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sesen Bio Inc
Glance View
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
See Also
What is Sesen Bio Inc's Other Items?
Other Items
-54m
USD
Based on the financial report for Dec 31, 2022, Sesen Bio Inc's Other Items amounts to -54m USD.
